专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20110124688A1 NICOTINE RECEPTOR AGONISTS IN STEM CELL AND PROGENITOR CELL RECRUITMENT 有权
标题翻译： NICOTINE RECEPTOR AGONISTS IN STEM CELL AND PROGENITCELL RECRUITMENT
公开(公告)号：US20110124688A1
公开(公告)日：2011-05-26
申请号：US12947575
申请日：2010-11-16
申请人： John Cooke , Frances Lauri Johnson , Anjali Pathak , James Jang , Philip Tsao , Christopher Heeschen
发明人： John Cooke , Frances Lauri Johnson , Anjali Pathak , James Jang , Philip Tsao , Christopher Heeschen
IPC分类号： A61K31/465 , A61P17/02 , A61P35/00
CPC分类号： A61K31/44 , A61K31/40 , A61K31/445 , A61K31/465
摘要： The present invention features methods for recruitment of bone marrow-derived stem cells (e.g., endothelial cell precursors, hematopoietic stem cells) by administration of nicotine or other nicotine receptor agonist. The methods of the invention can be used in, for example, treatment of conditions amenable to treatment by recruitment of bone marrow-derived stem cells (e.g., neutropenia).
摘要翻译：本发明的特征在于通过施用尼古丁或其他尼古丁受体激动剂募集骨髓来源的干细胞（例如，内皮细胞前体，造血干细胞）的方法。本发明的方法可用于例如治疗适于通过募集骨髓干细胞（例如中性粒细胞减少症）治疗的病症。

12. 发明授权

US06417205B1 Nicotine in therapeutic angiogenesis and vasculogenesis 失效
标题翻译：尼古丁治疗血管生成和血管发生
公开(公告)号：US06417205B1
公开(公告)日：2002-07-09
申请号：US09628226
申请日：2000-07-28
申请人： John Cooke , James Jang , Phillip Tsao , Christopher Heeschen
发明人： John Cooke , James Jang , Phillip Tsao , Christopher Heeschen
IPC分类号： A01N4340
CPC分类号： A61K31/44 , A61K31/445 , A61K31/465
摘要： The present invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease.
摘要翻译：本发明的特征在于通过施用尼古丁或其他尼古丁受体激动剂诱导血管发生的方法。通过本发明的方法诱导血管发生可用于例如治疗缺血综合征如冠状动脉或外周动脉疾病的治疗性血管发生。

13. 发明申请

US20060182731A1 Nicotine in therapeutic angiogenesis and vasculogenesis 失效
公开(公告)号：US20060182731A1
公开(公告)日：2006-08-17
申请号：US11404445
申请日：2006-04-13
申请人： John Cooke , James Jang , Phillip Tsao , Christopher Heeschen
发明人： John Cooke , James Jang , Phillip Tsao , Christopher Heeschen
IPC分类号： A61K38/44 , A61K31/519 , A61K31/473 , A61K31/445 , A61K31/40 , A61K31/137
CPC分类号： A61K31/137 , A61K31/40 , A61K31/445 , A61K31/473 , A61K31/519 , A61K38/446
摘要： The present invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease.

14. 发明申请

US20060167028A1 Nicotine in therapeutic angiogenesis and vasculogenesis 有权
公开(公告)号：US20060167028A1
公开(公告)日：2006-07-27
申请号：US11286850
申请日：2005-11-22
申请人： John Cooke , James Jang , Phillip Tsao , Christopher Heeschen
发明人： John Cooke , James Jang , Phillip Tsao , Christopher Heeschen
IPC分类号： A61K31/519 , A61K31/473 , A61K31/445 , A61K31/40 , A61K31/137
CPC分类号： A61K31/137 , A61K31/40 , A61K31/445 , A61K31/473 , A61K31/519 , A61K38/446
摘要： The present invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease.

15. 发明申请

US20050038079A1 Nicotine receptor agonists in stem cell and progenitor cell recruitment 有权
标题翻译：尼古丁受体激动剂干细胞和祖细胞募集
公开(公告)号：US20050038079A1
公开(公告)日：2005-02-17
申请号：US10779090
申请日：2004-02-13
申请人： John Cooke , Frances Johnson , Anjali Pathak , James Jang , Philip Tsao , Christopher Heeschen
发明人： John Cooke , Frances Johnson , Anjali Pathak , James Jang , Philip Tsao , Christopher Heeschen
IPC分类号： A61K31/40 , A61K31/44 , A61K31/445 , A61K31/465 , A61K31/4439
CPC分类号： A61K31/44 , A61K31/40 , A61K31/445 , A61K31/465
摘要： The present invention features methods for recruitment of bone marrow-derived stem cells (e.g., endothelial cell precursors, hematopoietic stem cells) by administration of nicotine or other nicotine receptor agonist. The methods of the invention can be used in, for example, treatment of conditions amenable to treatment by recruitment of bone marrow-derived stem cells (e.g., neutropenia).
摘要翻译：本发明的特征在于通过施用尼古丁或其他尼古丁受体激动剂募集骨髓来源的干细胞（例如，内皮细胞前体，造血干细胞）的方法。本发明的方法可用于例如治疗适于通过募集骨髓干细胞（例如中性粒细胞减少症）治疗的病症。

16. 发明申请

US20090155827A1 PIGF and FLT-1 as Prognostic Parameters for Cardiovascular Diseases 审中-公开
标题翻译： PIGF和FLT-1作为心血管疾病的预后参数
公开(公告)号：US20090155827A1
公开(公告)日：2009-06-18
申请号：US11666164
申请日：2005-10-25
申请人： Andreas M. Zeiher , Christopher Heeschen , Stefanie Dimmeler
发明人： Andreas M. Zeiher , Christopher Heeschen , Stefanie Dimmeler
IPC分类号： C12Q1/48 , C12Q1/00
CPC分类号： G01N33/74 , G01N33/6893 , G01N2800/324
摘要： The present invention refers to a use of an ex vivo method comprising the determination of PlGF and sFlt-1 in a sample for diagnosis, risk stratification and/or monitoring of a vascular disease with atherosclerotic etiology, in particular a coronary heart disease such a unstable angina pectoris or myocardial infarction, and/or for estimation of the probability of developing such a disease, as well as for identification of a patient supposed to benefit from a therapy by agents reducing the risk for a cardiovascular disease. In the method (i) a ratio of [PlGF=high:sFlt-1=low], and/or (ii) a PlGF concentration in the upper two tertiles of a reference collective, and an sFlt-1 concentration in the lower tertile of the reference collective, and/or (iii) a PlGF result above a PlGF reference value, and an sFlt-1 result below an sFlt-1-reference value indicate an elevated probability for an adverse event. The present invention also refers to the used method. The present invention further refers to a diagnostic kit and its use as well as to an assay element and its use.
摘要翻译：本发明涉及使用离体方法，其包括测定样品中的PlGF和sFlt-1用于具有动脉粥样硬化病因的血管疾病的诊断，风险分层和/或监测，特别是冠状动脉心脏病如不稳定心绞痛或心肌梗塞，和/或用于估计发生这种疾病的可能性，以及用于鉴定可减轻心血管疾病风险的药物治疗的患者。在方法（i）参考组的上两个三分位数中的[PlGF =高：sFlt-1 =低]和/或（ii）PlGF浓度的比例和下三分之一中的sFlt-1浓度的参考集合，和（iii）高于PlGF参考值的PlGF结果，低于sFlt-1参考值的sFlt-1结果表明不良事件的概率升高。本发明还涉及使用的方法。本发明还涉及诊断试剂盒及其用途以及测定元件及其用途。

17. 发明申请

US20080267927A1 Methods for improving cell therapy and tissue regeneration in patients with cardiovascular diseases by means of shockwaves 有权
标题翻译：通过冲击波改善心血管疾病患者的细胞治疗和组织再生的方法
公开(公告)号：US20080267927A1
公开(公告)日：2008-10-30
申请号：US12214660
申请日：2008-06-20
申请人： Andreas Lutz , Harald Eizenhofer , Andreas Michael Zeiher , Stefanie Drimmeler , Christopher Heeschen , Alexandra Aicher
发明人： Andreas Lutz , Harald Eizenhofer , Andreas Michael Zeiher , Stefanie Drimmeler , Christopher Heeschen , Alexandra Aicher
IPC分类号： A61K35/12 , A61P9/10
CPC分类号： A61H23/008 , A61B17/22004 , A61B2017/00247 , A61B2018/00392 , A61K35/44 , A61K38/1866 , A61K38/195 , A61K2300/00
摘要： Improving cell therapy and tissue regeneration in a patient suffering from a cardiovascular or a neurological disease by treating a tissue of the patient with shock waves and/or applying to the patient a therapeutically effective amount of stem cells and/or progenitor cells. Such treatment increases expression of chemoattractants, pro-angiogenic factors, and pro-survival factors. The chemoattractants can be, for example, vascular endothelial growth factor (VEGF) or stromal cell derived factor 1 (SDF-1). For example, the treated tissue can be located in the patient's heart or in a skeletal muscle of the patient, and the shock waves can be extracorporeal shock waves (ESW) or intracorporeal shock waves. The cardiovascular disease can have an ischemic or non-ischemic etiology. For example, the cardiovascular disease can be a myocardial infarction, ischemic cardiomyopathy, or a dilatative cardiomyopathy. For example, the neurological disease can be a peripheral neuropathy or neuropathic pain.
摘要翻译：通过用冲击波治疗患者的组织和/或向患者施用治疗有效量的干细胞和/或祖细胞来改善患有心血管或神经疾病的患者的细胞治疗和组织再生。这种治疗增加化学引诱物的表达，促血管生成因子和促生存因子。化学引诱物可以是例如血管内皮生长因子（VEGF）或基质细胞衍生因子1（SDF-1）。例如，经处理的组织可以位于患者的心脏或患者的骨骼肌中，冲击波可以是体外冲击波（ESW）或体内冲击波。心血管疾病可能有缺血性或非缺血性病因。例如，心血管疾病可以是心肌梗塞，缺血性心肌病或扩张型心肌病。例如，神经系统疾病可以是周围神经病变或神经性疼痛。

18. 发明申请

US20070274959A1 In Vitro Method for the Diagnosis of Cardiovascular Functionality of Bone Marrow-Precursor Cells (Bmp) and/or Circulation Precursor Cells Derived from Blood (Bdp) 有权
标题翻译：用于诊断来自血液（Bdp）的骨髓前体细胞（Bmp）和/或循环前体细胞的心血管功能的体外方法
公开(公告)号：US20070274959A1
公开(公告)日：2007-11-29
申请号：US10574380
申请日：2004-10-13
申请人： Andreas Zeiher , Christopher Heeschen , Stefanie Dimmeler
发明人： Andreas Zeiher , Christopher Heeschen , Stefanie Dimmeler
IPC分类号： A61K35/14 , G01N33/567
CPC分类号： G01N33/56966 , A61K2035/124 , G01N33/5005 , G01N2333/70589 , G01N2333/70596 , G01N2333/71 , G01N2333/755
摘要： The present invention relates to an in vitro method for the analysis of a sample from a mammal in connection with cardiovascular diseases, wherein the method comprises the following steps: a) isolating of bone marrow-precursor cells (BMPs) and/or blood-derived circulating precursor cells (BDPs) by means of cell specific surface markers, and b) detecting the cardiovascular functionality of the isolated BMPs and/or BDPs by means of a suitable migration assay. The method according to the invention can be employed as a kit in the context of the diagnosis and/or the prognosis of cardiovascular diseases, for the monitoring of their therapies and/or for a stratification for a prospective cell therapy with stem- and/or precursor cells in order to increase the perfusion of ischemic tissue or for a regeneration of tissue losses (e.g. heart insufficiency), respectively. In a further aspect, the present invention then relates to an in vitro method for isolating specific bone marrow-precursor cells by means of a suitable migration assay. According to the invention, these BMPs and/or BDPs can be used for the treatment of cardiovascular diseases, selected from the group consisting of stable coronary heart disease, acute coronary syndrome, acute myocardial infarction, chronic ischemic cardiomyopathy (ICMP), dilatative cardiomyopathy (DCM) or other causes for a heart insufficiency.
摘要翻译：本发明涉及用于分析哺乳动物与心血管疾病相关的样品的体外方法，其中所述方法包括以下步骤：a）分离骨髓前体细胞（BMP）和/或血液来源的通过细胞特异性表面标志物循环前体细胞（BDP），和b）通过合适的迁移试验检测分离的BMP和/或BDP的心血管功能。根据本发明的方法可以在心血管疾病的诊断和/或预后的背景下用作试剂盒，用于监测其疗法和/或用于具有茎和/或血管的前瞻性细胞治疗的分层，为了增加缺血组织的灌注或组织损失（例如心脏功能不全）的再生，分别为前体细胞。在另一方面，本发明涉及通过合适的迁移试验分离特异性骨髓前体细胞的体外方法。根据本发明，这些BMP和/或BDP可用于治疗心血管疾病，其选自稳定性冠心病，急性冠状动脉综合征，急性心肌梗死，慢性缺血性心肌病（ICMP），扩张性心肌病 DCM）或心脏功能不全的其他原因。

19. 发明申请

US20070042438A1 Scd4ol and placental growth factor (plgf) used as a biochemical marker combination in cardiovascular diseases 有权
标题翻译： Scd4ol和胎盘生长因子（plgf）用作心血管疾病中的生物化学标记物组合
公开(公告)号：US20070042438A1
公开(公告)日：2007-02-22
申请号：US10534985
申请日：2003-11-10
申请人： Andreas Zeiher , Christopher Heeschen , Stefanie Dimmeler , Christian Hamm
发明人： Andreas Zeiher , Christopher Heeschen , Stefanie Dimmeler , Christian Hamm
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , C07K14/70575 , G01N2333/96486 , G01N2800/32
摘要： The invention relates to novel markers of vascular inflammation and combinations thereof as diagnostic and prognostic tools in patients with cardiovascular diseases. The markers also act as tools that facilitate the selection of active ingredients for the treatment of such diseases, and finally act as starting points for the treatment of cardiovascular diseases. Furthermore, the invention relates to the creation of an individual risk profile of negative events that are associated with the progression of arteriosclerosis.
摘要翻译：本发明涉及血管炎症的新型标志物及其组合作为心血管疾病患者的诊断和预后工具。标记物也作为促进活性成分选择用于治疗这些疾病的工具，最终成为治疗心血管疾病的起点。此外，本发明涉及创建与动脉硬化进展相关的阴性事件的个体风险特征。

20. 发明授权

US09060915B2 Methods for improving cell therapy and tissue regeneration in patients with cardiovascular diseases by means of shockwaves 有权
标题翻译：通过冲击波改善心血管疾病患者的细胞治疗和组织再生的方法
公开(公告)号：US09060915B2
公开(公告)日：2015-06-23
申请号：US12214660
申请日：2008-06-20
申请人： Andreas Lutz , Harald Eizenhofer , Andreas Michael Zeiher , Stefanie Dimmeler , Christopher Heeschen , Alexandra Aicher
发明人： Andreas Lutz , Harald Eizenhofer , Andreas Michael Zeiher , Stefanie Dimmeler , Christopher Heeschen , Alexandra Aicher
IPC分类号： A61K48/00 , A61H23/00 , A61B17/22 , A61K38/18 , A61K38/19 , A61K35/44 , A61B17/00 , A61B18/00
CPC分类号： A61H23/008 , A61B17/22004 , A61B2017/00247 , A61B2018/00392 , A61K35/44 , A61K38/1866 , A61K38/195 , A61K2300/00
摘要： Improving cell therapy and tissue regeneration in a patient suffering from a cardiovascular or a neurological disease by treating a tissue of the patient with shock waves and/or applying to the patient a therapeutically effective amount of stem cells and/or progenitor cells. Such treatment increases expression of chemoattractants, pro-angiogenic factors, and pro-survival factors. The chemoattractants can be, for example, vascular endothelial growth factor (VEGF) or stromal cell derived factor 1 (SDF-1). For example, the treated tissue can be located in the patient's heart or in a skeletal muscle of the patient, and the shock waves can be extracorporeal shock waves (ESW) or intracorporeal shock waves. The cardiovascular disease can have an ischemic or non-ischemic etiology. For example, the cardiovascular disease can be a myocardial infarction, ischemic cardiomyopathy, or a dilatative cardiomyopathy. For example, the neurological disease can be a peripheral neuropathy or neuropathic pain.
摘要翻译：通过用冲击波治疗患者的组织和/或向患者施用治疗有效量的干细胞和/或祖细胞来改善患有心血管或神经疾病的患者的细胞治疗和组织再生。这种治疗增加化学引诱物的表达，促血管生成因子和促生存因子。化学引诱物可以是例如血管内皮生长因子（VEGF）或基质细胞衍生因子1（SDF-1）。例如，经处理的组织可以位于患者的心脏或患者的骨骼肌中，冲击波可以是体外冲击波（ESW）或体内冲击波。心血管疾病可能有缺血性或非缺血性病因。例如，心血管疾病可以是心肌梗塞，缺血性心肌病或扩张型心肌病。例如，神经系统疾病可以是周围神经病变或神经性疼痛。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式